GlassScriptPhysician profile
Wallace C Peterson
NPI 1760472039
$5,193.03
in general payments reported to CMS, 2019-2025
56 companies · $439 in 2025
The $439 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $341 · 2021: $611 · 2022: $1,038 · 2023: $1,136 · 2024: $1,010 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.44 |
| Education | $175.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $472.79 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $408.48 | 2019-2025 | |
| Celgene Corporation | $371.61 | 2019-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $309.96 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $299.41 | 2021-2023 | Epkinly, Imbruvica |
| Incyte Corporation | $297.76 | 2020-2024 | Jakafi, Pemazyre, Monjuvi |
| Merck Sharp & Dohme LLC | $257.95 | 2019-2024 | Keytruda, Welireg |
| Abbvie INC. | $253.88 | 2019-2025 | |
| Janssen Biotech, INC. | $226.14 | 2019-2022 | |
| Seagen INC. | $174.62 | 2020-2023 | Tukysa |
| Array Biopharma INC | $154.96 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Astrazeneca Pharmaceuticals LP | $142.34 | 2019-2024 | Imfinzi, Tagrisso |
| Eisai INC. | $118.44 | 2022-2025 | |
| Glaxosmithkline, LLC. | $109.17 | 2021-2025 | Zejula, Ojjaara, Jemperli |
| Lilly USA, LLC | $108.66 | 2024 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.